-
Mashup Score: 2New data at ASCO showcases the transformational potential of GSK's oncology portfolio | GSK US - 2 day(s) ago
Pivotal data will be shared from the DREAMM-8 and DREAMM-7 phase III trials.
Source: us.gsk.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 5Apprentices | GSK US - 15 day(s) ago
Our apprentice programs are a great way to kick start a brilliant career with us
Source: us.gsk.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 1Apprentices | GSK US - 16 day(s) ago
Our apprentice programs are a great way to kick start a brilliant career with us
Source: us.gsk.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 4Apprentices | GSK US - 17 day(s) ago
Our apprentice programs are a great way to kick start a brilliant career with us
Source: us.gsk.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 1Ovarian cancer | GSK US - 17 day(s) ago
Ovarian cancer originates in the ovaries of the fallopian tubes. In the US ~20,000 women are diagnosed for the first time annually
Source: us.gsk.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 4
Application supported by statistically significant and clinically meaningful progression-free and overall survival data from RUBY trial
Source: us.gsk.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 1New long-term data show SHINGRIX continues to provide high protection against shingles in adults aged 50 and over for more than a decade | GSK US - 1 month(s) ago
End-of-trial data show 79.7% efficacy in participants aged 50 years and over, six to 11 years after vaccination
Source: us.gsk.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 1GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA | GSK US - 1 month(s) ago
Submission based on results from pivotal phase III trial showing all primary endpoints met
Source: us.gsk.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 1GSK announces cap of $35 per month on U.S. patient out-of-pocket costs for its entire portfolio of asthma and COPD inhalers | GSK US - 2 month(s) ago
GSK is taking this action as part of its longstanding commitment to improving access to respiratory medicines in the U.S.
Source: us.gsk.comCategories: General Medicine News, Allergy-ImmunologyTweet
-
Mashup Score: 5GSK announces cap of $35 per month on U.S. patient out-of-pocket costs for its entire portfolio of asthma and COPD inhalers | GSK US - 2 month(s) ago
GSK is taking this action as part of its longstanding commitment to improving access to respiratory medicines in the U.S.
Source: us.gsk.comCategories: General Medicine News, PayerTweet
#News for #investors and #media: We’re pleased to share new data related to our oncology portfolio at #ASCO24, including two late-breaking presentations in #MultipleMyeloma and #RectalCancer. Read more: https://t.co/FpVUeDLArA https://t.co/lSkoveXcH6